Response to: 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)': reply from the authors.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 34878650.
- Also identified by DOI 10.1111/bjd.20944.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We believe that there is significant interest in the role of IL-1 in the pathomechanism of palmoplantar pustulosis. However, the APRICOT study failed to demonstrate a therapeutic effect of the IL-1 receptor antagonist. So, we recommend that the authors perform an additional subgroup analysis based on the presence or absence of plaque psoriasis.
Medical subject headings
- Exanthema
- Prunus armeniaca
- Psoriasis
- Skin Diseases, Vesiculobullous